Effectiveness of sumatriptan for acute treatment of migraine headache in an African population

African Journal of Neurological Sciences

Volumn 22, Issue 2, 2003, Pages

  Oluwole, Steven ^a   Bwala, S A ^b   Nwabueze, A C ^c   Davies, Abiola O ^d  

^a UNIVERSITY OF IBADAN   (Nigeria)

^b UNIVERSITY OF MAIDUGURI   (Nigeria)

^c UNIVERSITY OF NIGERIA   (Nigeria)

^d GlaxoWellcome Nigeria Limited   (Nigeria)

Author keywords

African; Afrique; C phal es; Headache; Migraine; Sumatriptan

Indexed keywords

SUMATRIPTAN;

ADULT; AFRICA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEOGRAPHY; HEADACHE; HUMAN; MALE; MIGRAINE; MIGRAINE AURA; NAUSEA AND VOMITING; NIGERIA; PHOBIA; PHOTOPHOBIA; POPULATION RESEARCH; RATING SCALE; STATISTICAL SIGNIFICANCE; SYMPTOM; TEACHING HOSPITAL; VISUAL ANALOG SCALE;

EID: 24744461664     PISSN: 10158618     EISSN: 10158618     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. ADAMS R, VICTOR M, ROPPER AH. Principles of Neurology. McGraw Hill, New York 1997; 185 - 187.
2. ADELMAN J, LIPTON R, FERRARI M, DIENER H, MCCARROLL K, VANDORMAEL K, LINES C. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001; 57: 1377-1383.
3. BIGAL M, TEPPER S: Ergotamine and dihydroergotamine: a review. Curr Pain Headache Rep 2003; 7: 55 - 62 .
4. CADY R, DODICK D. Diagnosis and treatment of migraine. Mayo Clin Proc 2002; 77: 255-261.
5. CARO G, CARO J, BRIEN J, ANTON S, JACKSON J. Migraine therapy:development and testing of a patient preference questionnaire. Headache 1998; 38: 602-607.
6. CARO J, GETSIOS D. Pharmacoeconomic evidence and considerations for triptan treatment of migraine. Expert Opin Pharmacother 2002; 3: 237 - 248.
7. CHALAL R, KWONG W, PUTNAM G, THOMPSON D, O'QUINN S, WEBSTER C, METZ A. Patient satisfaction with imitrex tablets 50 mg compared with their usual non-triptan prescription or over-the-counter migraine therapy. Cephalagia 2001; 21: 411.
8. Dahlof C. Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine:a review of data from clinical trials. Cephalagia 2001; 21(Suppl 1): 9-12.
9. FERRARI M, ROON K, LIPTON R, GOADSBY P. Oral triptans (serotonin 5-HT1B/ID agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001; 358: 1668-1675.
10. FREITAG F. Acute treatment of migraine and the role of triptans. Curr Neurol Neurosci Rep 2001; 1: 125-132.
11. GALLAGHER R, CUTRER F. Migraine: diagnosis, management, and new treatment options. Am J Manag Care 2002; 8(Suppl 3): S58-73.
12. GERAUD G. Migraine headache recurrence:relationship to clinical, pharmacological and pharmacokinetic properties of triptans. Cephalagia 2001; 21: 406.
13. GERAUD G, KEYWOOOD C, SENARD J. Migraine Headache Recurrence: Relationship to Clinical, Pharmacological, and Pharmacokinetic Properties of Triptans. Headache 2003 43: 367 - 388.
14. GOADSBY P, LIPTON R, FERRARI M. Migraine- current understanding and treatment. N Engl J Med 2002; 346: 257 - 270.
15. GOLDSTEIN D, ROON K, OFFEN W, RAMADAN N, PHEBUS L, JOHNSON K, SCHAUS J, FERRARI M. Selective serotonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001; 358: 1230-1234.
16. HEADACHE. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalagia 1988; 8: 1-96.
17. HUMPHREY P. How it started. Cephalagia 2001; 21(Suppl 1): 2-5 (2001).
18. IKEDA Y, JIMBO H, SHIMAZU M, SATOH K. Sumatriptan Scavenges Superoxide, Hydroxy, and Nitric Oxide Radicals: In Vitro Electron Spin resonance Study. Headache 2002; 42: 888 - 892.
19. JAMIESON D. The safety of triptans in the treatment of patients with migraine. Am J Med 2002; 112: 135-140 (2002).
20. JOHNSON D, ROLLEMA H, SCHMIDT A, MCHARG A. Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol 2001; 425: 203 - 210.
21. KWASA T, JOWI J, AMAYO E. Efficacy and tolerability of oral sumatriptan in the treatment of acute migraine. East Afr Med J 1995; 72: 479-482.
22. LIPTON R, GOADSBY P, MCCARROLL K, ALLEN C, LINES C. Are migraine patients who are pain free at 2 h after treatment also more likely to be free of nausea. Cephalagia 2001; 21: 422.
23. LIPTON R, HAMELSKY S, DAYNO J. What do patients with migraine want from acute migraine treatment? Headache 2002; 42(Suppl 1): 3-9.
24. MARCUS D. Establishing a standard of speed for assessing the efficacy of the serotonin1B/1D agonists (Triptans). Arch Neurol 2001; 58: 1056-1058.
25. MATHEW N. Comparison of therapeutic gains over sumatriptan for eletriptan, naratriptan, rizatriptan, and zolmitriptan:a review of six clinical studies. Cephalagia 2001; 21: 407.
26. MATHEW N, SCHOENEN J, WINNER P, MUIRHEAD N, SIKES C. Comparative Efficacy of Eletriptan 40 mg Versus Sumatriptan 100 mg. Headache 2003; 43: 214 - 222.
27. MAY A, GOADSBY P. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cereb Blood Flow Metab 1999; 19: 115 - 127.
28. NAPPI G, SANDRINI G, SANCES G. Tolerability of the triptans: clinical implications. Drug Saf 2003; 26: 93 - 107.
29. PARSONS A, STRIJBOS P. The neural versus vascular hypothesis of migraine and cortical spreading depression. current Opinion in Pharmacology 2003; 3: 73 - 77.
30. PASCUAL J, MUNOZ R, LEIRA R. An open preference study with sumatriptan 50 mg and zolmitriptan 2.5 mg in 100 migraine patients. Cephalagia 2001; 21: 680-684.
31. PETROBON D, STRIESSNIG J. Neurobiology of migraine. Nature Reviews Neurosciences 2003; 4: 386 - 398.
32. RAPOPORT A, TEPPER S. Triptans are all different. Arch Neurol 2001; 58: 1479 - 1480.
33. RAPOPORT A, TEPPER S, BIGAL M, SHEFTELL F. The triptans formulations: how to match patients and products. CNS Drugs 2003; 17: 431 -437.
34. REEDER C, STEADMAN S, GOLDFARB S. Economic comparison of oral triptans for management of acute migraine:implications for managed care. Am J Manag Care 2002; 8(Suppl 3): S80-84.
35. ROBBINS L. Triptans vs analgesics:patients preference. Cephalagia 2001; 21: 406.
36. ROON K, LIPTON R, GOADSBY P, FERRARI M. Placebo in triptan trials:efficacy, tolerability and consistency. Cephalagia 2001; 21: 405.
37. RYAN R. Patient treatment preferences and the 5-HT1B/1D agonists. Arch Intern Med 2001; 161: 2545-2553.
38. SALONEN R. The Sumatriptan difference. Cephalagia 2001; 21: 18-20.
39. SANDRINI G, FARKKILA M, BURGESS G, FORSTER E, HAUGHIE S. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002; 59: 1210-7.
40. SAPER J. What matters is not the differences between the triptans, but the differences between patients. Arch Neurol 2001; 58: 1481-1482.
41. SHEFTELL F, RYAN R, PITMAN V. Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine: A Multicenter, Double-Blind, Placebo-Controlled Study Conducted in the United States. Headache 2003; 43: 202-213.
42. TEPPER S. Safety and rational use of the triptans. Med Clin North Am 2001; 85: 959-970.
43. van den BROEK R, P BHALLA P, MAASSENVanDENBRINK A, de VRIES R, SHARMA H, SAXENA P. Characterisation of sumatriptan-induced contractions in human isolated blood vessels using selective 5-HTIB and 5-HT1D receptor antagonists and in situ hybridisation. Cephalagia 2002; 22: 83-93.
44. WELCH K. Sumatriptan and naratriptan tolerability and safety: and update of post-marketing experience. Cephalagia 2001; 21(Suppl 1): 25-28.
45. WHITAKER J. Triptans for Migraine Headache: Therapeutic progress meets a heterogenous patient response. Arch Neurol 2001; 58: 1482-1483.